AU2006313724B2 - Staurosporine derivatives for use in alveolar rhabdomyosarcoma - Google Patents

Staurosporine derivatives for use in alveolar rhabdomyosarcoma Download PDF

Info

Publication number
AU2006313724B2
AU2006313724B2 AU2006313724A AU2006313724A AU2006313724B2 AU 2006313724 B2 AU2006313724 B2 AU 2006313724B2 AU 2006313724 A AU2006313724 A AU 2006313724A AU 2006313724 A AU2006313724 A AU 2006313724A AU 2006313724 B2 AU2006313724 B2 AU 2006313724B2
Authority
AU
Australia
Prior art keywords
typically
lower alkyl
radicals
phenyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006313724A
Other languages
English (en)
Other versions
AU2006313724A1 (en
Inventor
Ralf Amstutz
Beat W. Schafer
Marco Wachtel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universitaet Institut fuer Medizinische Virologie
Original Assignee
Zurich Universitaet Institut fuer Medizinische Virologie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zurich Universitaet Institut fuer Medizinische Virologie filed Critical Zurich Universitaet Institut fuer Medizinische Virologie
Publication of AU2006313724A1 publication Critical patent/AU2006313724A1/en
Application granted granted Critical
Publication of AU2006313724B2 publication Critical patent/AU2006313724B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2006313724A 2005-11-14 2006-11-13 Staurosporine derivatives for use in alveolar rhabdomyosarcoma Ceased AU2006313724B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73622205P 2005-11-14 2005-11-14
US60/736,222 2005-11-14
PCT/EP2006/068410 WO2007054579A1 (en) 2005-11-14 2006-11-13 Staurosporine derivatives for use in alveolar rhabdomyosarcoma

Publications (2)

Publication Number Publication Date
AU2006313724A1 AU2006313724A1 (en) 2007-05-18
AU2006313724B2 true AU2006313724B2 (en) 2010-12-23

Family

ID=37758863

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006313724A Ceased AU2006313724B2 (en) 2005-11-14 2006-11-13 Staurosporine derivatives for use in alveolar rhabdomyosarcoma

Country Status (10)

Country Link
US (1) US7973032B2 (enExample)
EP (1) EP1951255A1 (enExample)
JP (1) JP5308820B2 (enExample)
KR (1) KR20080067654A (enExample)
CN (1) CN101304749A (enExample)
AU (1) AU2006313724B2 (enExample)
BR (1) BRPI0618571A2 (enExample)
CA (1) CA2629478C (enExample)
RU (1) RU2443421C2 (enExample)
WO (1) WO2007054579A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025132479A1 (en) * 2023-12-18 2025-06-26 Institut National de la Santé et de la Recherche Médicale Flt3 inhibitor for modulating macrophages polarization

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004761A1 (en) * 1995-07-28 1997-02-13 Trustees Of Boston University Methods and compositions for treating cell proliferative disorders
WO2003037347A1 (en) * 2001-10-30 2003-05-08 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
US20030096875A1 (en) * 1994-08-10 2003-05-22 Graham Burton Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents
WO2004112794A2 (en) * 2003-06-18 2004-12-29 Novartis Ag New pharmaceutical uses of staurosporine derivatives
WO2005027971A1 (en) * 2003-09-19 2005-03-31 Novartis Ag Treatment of gastrointestinal stromal tumors with imatinib and midostaurin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
WO1997040830A1 (en) * 1996-05-01 1997-11-06 Eli Lilly And Company Therapeutic treatment for vegf related diseases
RU2269315C2 (ru) * 2004-05-24 2006-02-10 Рашид Кямиль Оглы Гусейнов Способ соединения сосудов и устройство для герметизации надреза сосуда и перерезания стенки сосуда

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096875A1 (en) * 1994-08-10 2003-05-22 Graham Burton Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents
WO1997004761A1 (en) * 1995-07-28 1997-02-13 Trustees Of Boston University Methods and compositions for treating cell proliferative disorders
WO2003037347A1 (en) * 2001-10-30 2003-05-08 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
WO2004112794A2 (en) * 2003-06-18 2004-12-29 Novartis Ag New pharmaceutical uses of staurosporine derivatives
WO2005027971A1 (en) * 2003-09-19 2005-03-31 Novartis Ag Treatment of gastrointestinal stromal tumors with imatinib and midostaurin

Also Published As

Publication number Publication date
AU2006313724A1 (en) 2007-05-18
US20080280880A1 (en) 2008-11-13
KR20080067654A (ko) 2008-07-21
EP1951255A1 (en) 2008-08-06
JP5308820B2 (ja) 2013-10-09
CA2629478A1 (en) 2007-05-18
CA2629478C (en) 2013-10-15
BRPI0618571A2 (pt) 2011-09-06
JP2009515858A (ja) 2009-04-16
RU2443421C2 (ru) 2012-02-27
RU2008123382A (ru) 2009-12-27
CN101304749A (zh) 2008-11-12
US7973032B2 (en) 2011-07-05
WO2007054579A1 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
EP1441737B1 (en) Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
AU2004244747B2 (en) Staurosporine derivatives for hypereosinophilic syndrome
AU2004262927B2 (en) Combinations comprising staurosporines
AU2006313724B2 (en) Staurosporine derivatives for use in alveolar rhabdomyosarcoma
AU2005313556B2 (en) Use of staurosporine derivatives for the treatment of multiple Myeloma
US20080207496A1 (en) Organic compound
WO2006021456A1 (en) Combination comprising a staurosporine and a cyp3a4 inhibitor
WO2008043811A1 (en) Staurosporine derivatives and radiation
MX2008006287A (es) Derivados de estaurosporina para utilizarse en rabdomiosarcoma alveolar.
AU2008201869A1 (en) Staurosporine derivatives for hypereosinophilic syndrome
AU2008202050A1 (en) Combinations comprising staurosporines
HK1068262B (en) Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired